Stephens Inc. AR Decreases Stake in Pfizer Inc. $PFE

Stephens Inc. AR reduced its position in Pfizer Inc. (NYSE:PFE) by 9.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 327,268 shares of the biopharmaceutical company’s stock after selling 35,698 shares during the period. Stephens Inc. AR’s holdings in Pfizer were worth $8,149,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of PFE. Franklin Resources Inc. raised its stake in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. Neuberger Berman Group LLC raised its stake in shares of Pfizer by 203.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after purchasing an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Pfizer by 48.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Pfizer by 120.9% in the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock valued at $230,986,000 after purchasing an additional 5,202,884 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Pfizer Trading Down 1.7%

Pfizer stock opened at $25.31 on Friday. The firm has a 50 day simple moving average of $26.98 and a 200-day simple moving average of $26.19. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a market capitalization of $144.25 billion, a PE ratio of 19.32 and a beta of 0.35. Pfizer Inc. has a 12-month low of $22.45 and a 12-month high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Morgan Stanley upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. CICC Research initiated coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.84.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.